Form 4: Organon & Co. Corporate Controller Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Kathryn DiMarco, Corporate Controller of Organon & Co., reports transactions involving common stock and restricted stock units.
Summary
- Kathryn DiMarco, Corporate Controller of Organon & Co., filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
- The transactions occurred on March 31, 2025, and involved the vesting of restricted stock units (RSUs) and the corresponding acquisition and disposition of common stock.
- Specifically, RSUs granted in 2022, 2023 and 2024 vested, resulting in the acquisition of 10,638, 8,503 and 4,294 shares of common stock, respectively.
- Simultaneously, shares were disposed of to cover tax obligations at a price of $14.51 per share.
- Following these transactions, DiMarco directly owns 38,740 shares of Organon common stock and 0 restricted stock units.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, indicating standard compensation practices. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Positives
- The vesting of RSUs indicates a continued alignment of the Corporate Controller's interests with those of the company and its shareholders.
Future Outlook
The remaining RSUs granted in 2024 will vest on March 29, 2026 and March 29, 2027. The RSUs granted on March 31, 2025 will vest in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates standard compensation practices involving stock-based awards.
Comparison to Industry Standards
- Stock-based compensation is a common practice among publicly traded companies to align management's interests with shareholders.
- Vesting schedules of three years are typical for restricted stock units.
- Companies like Pfizer, Teva, and Mylan also utilize stock-based compensation as part of their overall executive compensation packages.
Stakeholder Impact
- The vesting of RSUs has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/31/2022 | RSUs were awarded. |
| 03/31/2023 | RSUs were awarded. |
| 03/29/2024 | RSUs were granted. |
| 03/31/2025 | Date of earliest transaction; RSUs vested; RSUs were granted. |
| 03/31/2026 | One-third of RSUs granted on March 31, 2025, will vest. |
| 03/31/2027 | One-third of RSUs granted on March 31, 2025, will vest. |
| 03/31/2028 | One-third of RSUs granted on March 31, 2025, will vest. |
| 04/02/2025 | Date of Form 4 filing. |
Keywords
Form 4, beneficial ownership, Organon & Co., Kathryn DiMarco, Corporate Controller, common stock, restricted stock units, RSUs, vesting, transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.